[Augmentation of therapeutic effect of adoptive immunotherapy through a synergy between transferred killer cells and host's fresh lymphocytes].
Among several approaches to augment the therapeutic effect of adoptive immunotherapy, we focused the antitumor synergy between transferred killer cells and host's fresh lymphocytes. Immunotherapy models using murine tumors or clinical experiments revealed that preadministration of immunostimulator such as OK-432, followed by chemotherapeutic agents such as cyclophosphamide, can induce host's non-cytotoxic fresh lymphocytes that act synergistically with cultured killer cells against autologous tumor cells. Immuno-chemo-lymphocytotherapy (a sequential treatment with OK-432, chemotherapy and adoptive immunotherapy) is useful to treat the patients with advanced cancer even if the number of transferred lymphocytes is limited.
Kan
N
N
First Department of Surgery, Kyoto University, Faculty of Medicine, Japan.
Yamasaki
S
S
Harada
T
T
Satoh
K
K
Ichinose
Y
Y
Moriguchi
Y
Y
Kodama
H
H
Ohgaki
K
K
D000818:Animals; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000627:therapeutic use; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000637:transplantation*; D008214:Lymphocytes / Q000276:immunology*; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D010844:Picibanil / Q000627:therapeutic use
D007376:Interleukin-2; D010844:Picibanil; D003520:Cyclophosphamide